Skip to main content

Xiaofei Wang

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2721, Durham, NC 27710
2424 Erwin Road Suite 1102, 11080 Hock Plaza, Duke Box 272, Durham, NC 27705

Overview


Survival Analysis
Causal Inference
Design and Analysis of Clinical Trials
Methods for Diagnostic and Predictive Medicine
Analysis of Data from Multiple Sources

Current Appointments & Affiliations


Professor of Biostatistics & Bioinformatics · 2021 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Member of the Duke Cancer Institute · 2015 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020.

Journal Article JTO Clin Res Rep · March 2025 INTRODUCTION: Although lobectomy has long been the standard of surgical treatment for early-stage NSCLC, segmental and wedge resections have become another option often used over the past two decades. METHODS: To examine the trends over time in the utiliza ... Full text Link to item Cite

Network Meta-Analysis With Individual Participant-Level Data of Time-to-Event Outcomes Using Cox Regression.

Journal Article Stat Med · February 28, 2025 The accessibility of individual participant-level data (IPD) enhances the evaluation of moderation effects of patient covariates. It facilitates the provision of accurate estimation of intervention effects and confidence intervals by incorporating covariat ... Full text Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

Journal Article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item Cite
View All Publications

Recent Grants


AFT-57 Trials (5d)

ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2023 - 2028

Methods to improve efficiency and robustness of clinical trials using information from real-world data with hidden bias

ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2023 - 2026

Alliance for Clinical Trials in Oncology

ResearchPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2019 - 2026

View All Grants

Education, Training & Certifications


University of North Carolina, Chapel Hill · 2003 Ph.D.